11/13
01:09 am
kzr
Kezar Life Sciences GAAP EPS of -$1.53 beats by $0.42 [Seeking Alpha]
Low
Report
Kezar Life Sciences GAAP EPS of -$1.53 beats by $0.42 [Seeking Alpha]
11/12
04:01 pm
kzr
Kezar Life Sciences Reports Third Quarter 2025 Financial Results
Low
Report
Kezar Life Sciences Reports Third Quarter 2025 Financial Results
11/7
07:01 am
kzr
Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025
Low
Report
Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025
10/18
07:31 am
kzr
Kezar Life Sciences (NASDAQ:KZR) was downgraded by analysts at TD Cowen from a "strong-buy" rating to a "strong sell" rating.
Low
Report
Kezar Life Sciences (NASDAQ:KZR) was downgraded by analysts at TD Cowen from a "strong-buy" rating to a "strong sell" rating.
10/17
08:46 am
kzr
Kezar Life Sciences (NASDAQ:KZR) had its "market perform" rating reaffirmed by analysts at William Blair.
High
Report
Kezar Life Sciences (NASDAQ:KZR) had its "market perform" rating reaffirmed by analysts at William Blair.
10/17
08:06 am
kzr
Kezar Life Sciences (NASDAQ:KZR) was given a new $5.00 price target on by analysts at Wells Fargo & Company.
Medium
Report
Kezar Life Sciences (NASDAQ:KZR) was given a new $5.00 price target on by analysts at Wells Fargo & Company.
10/17
06:03 am
kzr
Kezar Life Sciences (NASDAQ:KZR) was downgraded by analysts at Jefferies Financial Group Inc. to a "hold" rating.
High
Report
Kezar Life Sciences (NASDAQ:KZR) was downgraded by analysts at Jefferies Financial Group Inc. to a "hold" rating.
10/16
04:33 pm
kzr
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives [Yahoo! Finance]
Medium
Report
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives [Yahoo! Finance]
10/16
04:05 pm
kzr
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives
High
Report
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives
9/13
01:07 am
kzr
Kezar Life Sciences (NASDAQ:KZR) was upgraded by analysts at
Wall Street
Low
Report
Kezar Life Sciences (NASDAQ:KZR) was upgraded by analysts at
Wall Street